No increased risk of major malformation following first trimester fluoroquinolone use

Researchers from the Pregnancy and Drug Information Center in Tokyo have published a comparative cohort study comparing fetal malformation outcomes between those exposed to (i) fluoroquinolones (fluoroquinolone group), (ii) β-lactams (infectious control group), or (iii) other agents considered to be nonteratogenic in humans (nonteratogenic control group) during the first trimester. The incidence of major congenital anomalies was not found to differ significantly between these groups. More information can be found here.

Photo by CDC on Unsplash